Nine Names
Language English

Nine Names LLC

Biomedical claims, checked before they move.

Nine Names maps the source, audits the pipeline, tests cohort support, and marks what survives, narrows, or stays held.

Company
Nine Names LLC
Director
Jixiang Leng
Director correspondence
leng.jixiang@ninenames.com
Audit map Send only the frame Open full review page

You can stop there. We ask before anything more is shared.

Audit map

Move toward what you need.

The page brings one path forward at a time: source, methods, verdict, handoff, or contact. Nothing clicks unless you choose it.

Move toward what you want to check. I will bring one path forward and keep the rest quiet.

  1. Read Same paths, no motion.
  2. Notice Nearby choices get clearer.
  3. Lean Cursor movement suggests one next path.
Company1 Source3 Methods4 Verdict1 Workflow2 Handoff2 Channel2
Path Ready Now: Source Ledger Likely: Source map Move gently. I will keep one likely path in view.

The map only changes the view. It never auto-clicks, auto-submits, tracks you, or changes the public record.

Choose the safest start

Start in the safest lane.

Every lane starts with public-safe information. No login, upload, or sensitive file is needed.

Scientific reviewer I want to inspect the method.

Open the full review path for sources, checks, failure modes, and status labels.

 Clinical or disease team I need to know if this is worth follow-up.

Send role, source link, and decision context. Keep patient files out.

 Family or advocate I only want to ask a safe question.

Start with a public source and one question. We do not ask for treatment details.

 Partner or diligence I need a controlled handoff.

Share organization, purpose, and confidentiality needs. We route before review.

30-second path

Send the frame, not the files.

If you have a source link and a decision that depends on it, that is enough to start.

  1. 01 Role

    Who you are in the review.

  2. 02 Claim

    What you want checked.

  3. 03 Source

    Paper, figure, dataset page, or link.

  4. 04 Decision

    What this could affect.

Open short email

Fit check

Use Nine Names when the method under a biomedical claim needs pressure.

You do not need a private dataset to start. A source link and decision context are enough for first routing.

Send only the frame
Good fit

A paper, dataset, workflow, figure, or claim could affect funding, review, strategy, or care.

Do not send yet

Patient files, raw private data, credentials, or treatment questions stay out of first contact.

You stay in control

We scope the review first. Nothing becomes public from a first email.

After you send it

We route before review

We check scope first, then decide whether a public answer, reviewer handoff, or hold is appropriate.

  1. 01 Send only the frame

    Your role, the claim, source link, and what decision this affects.

  2. 02 We check scope and safety first.

    No patient files, credentials, prescriptions, emergencies, or private datasets.

  3. 03 We route to public answer, reviewer handoff, or hold.

    You decide whether anything more is shared.

What we do

Three hard gates before a claim sharpens.

Each capability maps to a part of the audit trail reviewers can ask for.

Source Ledger

Map every public statement to a traceable source, status label, and missing-artifact note.

Break Tests

Challenge QC filters, normalization defaults, and donor-level support before a claim moves.

Verdict Line

Survives, caveat, and held labels come only after the audit trail is written.

Recent audit spotlight: ALS

We audited whether ALS signals survived donors, cohorts, and pipeline checks.

ALS is the current reviewed example, not the company category. The spotlight shows how Nine Names turns a biological claim into checks before language.

Donor-level audit 80 dataset-by-axis tests; 23 initial cell-level flags; 1 of those 23 survived donor-level correction.

Three rows were donor-significant overall; only one was an initial headline flag.

Cross-cohort tiering Five ALS-relevant cohorts across cortex, spinal cord, PBMC, and fibroblast data.

Signals are separated by source, assay, and replication posture.

QC / normalization stress Pipeline defaults were treated as audit targets, not background settings.

Filters, anchors, and pooled-cell certainty can all change the story.

Reviewer boundary Public summary first; source tables by qualified review.

No treatment advice or prescriptions; physicians and PIs decide.

Reviewer path

Need the full audit surface?

Source maps, metrics, method rows, and status labels for qualified review.

Open full review page

Contact

Official review contact

Send role, claim, and source question. Do not send patient files or treatment requests.

  1. Send only the frame

    Your role, the claim, source link, and what decision this affects.

  2. Keep sensitive files out

    No patient files, credentials, prescriptions, emergencies, or private datasets.

  3. We route before review

    We check scope first, then decide whether a public answer, reviewer handoff, or hold is appropriate.

After you send it
  • We check scope and safety first.
  • We route to public answer, reviewer handoff, or hold.
  • You decide whether anything more is shared.
  • If it is not a fit, we can say so without asking for files.
A first note can be this small:

If unsure, send only: Can you route this? [link]

  • My role is...
  • The claim I want reviewed is...
  • The source link or paper is...
  • The decision this affects is...

No patient files or private data in the first email.

Open short email Opens a one-line email. Add details only if easy.
If the email app does not open

Use the address and subject below, then paste the same small frame above.

Send to
leng.jixiang@ninenames.com
Subject
Nine Names review request

If it is not a fit, we can say so without asking for files.

Copyable draft